Eli Lilly has gained rights to use ImmunoGen’s maytansinoid targeted antibody payload (TAP) technology to develop a specified number of antibody-drug conjugates for the potential treatment of cancer. ImmunoGen will receive US$20 M upfront and could receive up to US$200 M in milestone payments for each licence taken as well as royalties on sales of any resulting products. With this deal, Eli Lilly has joined ImmunoGen’s list of TAP partners that includes Amgen, Bayer Healthcare, Roche, Novartis and Sanofi.